The edition · Urology
Adding gemcitabine to BCG cleared 96% of BCG-exposed bladder cancers early
Plus why progression-free survival is a shaky stand-in for survival in kidney cancer, an inherited signal for prostate-cancer progression, and what the refreshed PSA evidence shows.
The edition in brief
Today's urology edition leads on bladder cancer. In a phase I trial of 25 patients with BCG-exposed high-grade non-muscle-invasive bladder cancer, alternating intravesical gemcitabine and BCG (GemBCG) was well tolerated and produced a 96% complete clinical response at six months — promising early data now being tested against BCG retreatment in a phase III trial. A meta-analysis of 62 kidney-cancer trials found progression-free survival and objective response only moderately correlate with overall survival, so they are unreliable surrogates and overall survival should remain the anchor. A prospective cohort identified germline variants in steroidogenic genes nominally associated with progression of localized prostate cancer to lethal disease, an early step toward inherited risk stratification. A pearl reiterates that visible haematuria is bladder cancer until proven otherwise. The practice-changer is the updated Cochrane review of PSA screening: it likely reduces prostate-cancer-specific mortality modestly but shows little clear effect on overall mortality, reinforcing screening as a shared, preference-sensitive decision.
Alternating gemcitabine and BCG cleared 96% of BCG-exposed bladder cancers at six months
GemBCG gave a 96% six-month complete response in BCG-exposed bladder cancer in phase I — promising, but await the randomised phase III before changing practice.
In kidney cancer, progression-free survival is a weak stand-in for overall survival
Treat progression-free survival and response rate in metastatic kidney cancer as unreliable surrogates — keep overall survival as the anchor when counselling on new drugs.
Inherited hormone-pathway variants flagged prostate cancers likely to turn lethal
Germline steroidogenic-pathway variants may eventually refine prostate-cancer risk stratification, but this is early, unreplicated work and not a test to order now.
Visible haematuria in an adult is bladder cancer until proven otherwise
Investigate any adult with visible haematuria for urothelial cancer with cystoscopy and upper-tract imaging, rather than treating it as infection.
Updated Cochrane review: PSA screening cuts prostate-cancer death, but not clearly overall mortality
Offer PSA screening as a shared decision — it modestly reduces prostate-cancer death but has not been shown to lower overall mortality, against the harms of overdiagnosis.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free